

At a Glance

- Start of Operations: January 2004
- Total Financing: € 22 million
- Headcount: 17

Management Team

- Dr. Herbert Stadler, CEO, Vorstand
- Jesper Wiklund, CBO, Vorstand
- Dr. Michael Bös, Research & Development
- Dr. Luc St-Onge, Patents & Licenses
- Dr. Inge Sillaber, Behavioural Pharmacology
- Dr. Marcelo Paez-Pereda, Gene Discovery and Validation

Supervisory Board

- Dr. Joachim Rothe, Chairman
- Prof. Dr. Domenico Valerio, Vice-Chairman
- Dr. Christoph Antz
- Alex Martin
- Prof. Dr. Wolfgang Wurst

Scientific Advisory Board

- Prof. Dr. Hanns Möhler, Chairman
- Prof. Dr. Dr. Florian Holsboer
- Prof. Dr. Wolfgang Wurst
- Prof. Dr. Nick Barden
- Prof. Dr. Karl-Heinz Altmann
- Prof. Hugo Kubinyi
- Prof. Dr. Walter Stühmer
- Prof. Dr. Dr. Kay Brune
- Prof. Dr. Adriaan Sitsen

Investors

- Life Sciences Partners
- EMBL Technology Fund
- AESCAP
- KfW
- BayernKapital
- Adamant Biomedical Investments
- Sunrise Water Ltd.

Contact

Sabina van den Brandt
Affectis Pharmaceuticals AG
Kraepelinstrasse 2
80804 Munich
Germany
Tel. +49 (0)89 306 22 591
Fax. +49 (0)89 306 22 370
info@affectis.com
www.affectis.com

Novel Drugs for the Treatment of Depression and Schizophrenia

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders, especially depression and schizophrenia. The Company started operations in January 2004 and is located on the premises of the Max-Planck-Institute of Psychiatry (MPI) in Munich, Germany. Affectis has unique capabilities to discover and develop drugs based on pioneering findings in the field of psychiatric disorders. The Company's drug discovery programme targets two interrelated pathways so far unknown in the context of depression and schizophrenia.

Today's antidepressant market is dominated by therapeutic concepts that are decades old. Shortcomings of existing drugs range from delayed onset of action to a significant rate of non-responders. Affectis' discovery programmes carry the promise to develop entirely new classes of antidepressant drugs that act fast and in a large number of patients.

Affectis' Pipeline

The lead candidate targeting the P2X7 pathway is expected to enter preclinical trials in early 2007. In addition, Affectis has recently in-licensed the exclusive right for the second medical use of Cimicoxib, a selective Cox-2 inhibitor targeting a pathway distinct from P2X7. A Phase II clinical program for depression and schizophrenia is presently in preparation and will be initiated early 2007. Affectis' research pipeline includes a pool of additional targets that are presently being validated.

Business Model

The Company has the capabilities to move its proprietary drug candidates all the way through from discovery to clinical development in phase II. In parallel, Affectis will selectively enter into partnerships with top-tier companies to cover all aspects of the drug development chain, including commercialisation.

Collaborations

Research collaborations are ongoing with the Max-Planck-Institute of Psychiatry, Munich, the Institute of Psychiatry at the University of Munich, the University of Laval in Quebec, Canada, and the Universidad de Buenos Aires, Argentina.

Furthermore, Affectis will evaluate co-development partnerships with the pharmaceutical industry. Affectis' extensive expertise in behavioural pharmacology has already attracted high-profile parties like Novartis, Masterfoods, Mitsubishi Pharma, and Organon for research agreements.

Experienced Team

In addition to an experienced management team headed by a serial biotech entrepreneur, the Company is drawing on extensive expertise of its Supervisory Board members as well as its industry advisors, covering different aspects of the drug discovery and development process.